# Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis

**Authors:** Yan Wang, Xiu Sun, Junyan Zhang, Qi Mei

PMC · DOI: 10.1007/s12072-024-10642-0 · Hepatology International · 2024-03-02

## Full-text entities

- **Diseases:** chronic hepatitis B (MESH:D019694), dyslipidemia (MESH:D050171)
- **Chemicals:** tenofovir alafenamide (MESH:C442442)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11014805/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC11014805/full.md

---
Source: https://tomesphere.com/paper/PMC11014805